Vessela Vassileva - Concepedia

Concepedia

Author

Vessela Vassileva

University College London ORCID

Also Known As

V VASSILEVA, V Vassileva, V. Vassileva, Vassileva, V, Vessela Vassileva

68

Publications

1.3K

Citations

14

H-Index

50

Concepts

All Affiliations

University College London University of Toronto CRUK Lung Cancer Centre of Excellence Cancer Institute (WIA)Imperial College London

VV

About

Vessela Vassileva is an author at University College London specializing in medicine, pharmacology, and drug delivery systems.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	480
2	Engineering	3	3	205
3	Biomedical Engineering	2	2	98
4	Biomolecular Engineering	2	2	126
5	Natural Sciences	1	1	54

Vessela Vassileva

×

17

Publications

1.3K

Citations

14

H-Index

	Year	Citations
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer Jermaine Coward, Hagen Kulbe, Probir Chakravarty, Clinical Cancer Research	2011	380
Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody–drug conjugate (ADC) João P. M. Nunes, Maurício Morais, Vessela Vassileva, Chemical Communications	2015	112
Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Vessela Vassileva, Anna Millar, Laurent Briollais, PubMed Genome InstabilityEngineeringMsi+ EcSomatic VariantGenetic Disorder	2002	107
IMPACT OF ENDOTOXIN-INDUCED CHANGES IN P-GLYCOPROTEIN EXPRESSION ON DISPOSITION OF DOXORUBICIN IN MICE Georgy Hartmann, Vessela Vassileva, Micheline Piquette‐Miller Drug Metabolism and Disposition	2005	83
Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer Vessela Vassileva, Christine Allen, Micheline Piquette‐Miller Molecular Cancer Therapeutics	2008	79
Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer Goran H. Mohammad, Vessela Vassileva, Pilar Acedo, Cancers Chemoprevention StrategyMetabolic RemodelingTumor BiologyOncologyPancreatic Cancer	2019	77
Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model Vessela Vassileva, Justin Grant, Raquel De Souza, Cancer Chemotherapy and Pharmacology Drug TargetingOncologyPolymer-drug ConjugateMedicineGynecology	2007	72
Pyridazinediones deliver potent, stable, targeted and efficacious antibody–drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody E. Robinson, João P. M. Nunes, Vessela Vassileva, RSC Advances Medicinal ChemistryDrug TargetDrug TargetingMedicineDrug Discovery	2017	72
In vitro and in vivo characterization of a novel biocompatible polymer–lipid implant system for the sustained delivery of paclitaxel Emmanuel A. Ho, Vessela Vassileva, Christine Allen, Journal of Controlled Release Cell-based Drug DeliveryNanomedicineVivo CharacterizationEngineeringPolymer-drug Conjugate	2005	68
Use of a next generation maleimide in combination with THIOMAB™ antibody technology delivers a highly stable, potent and near homogeneous THIOMAB™ antibody-drug conjugate (TDC) João P. M. Nunes, Vessela Vassileva, E. Robinson, RSC Advances ImmunologyImmunotherapeuticsChemical BiologyImmunotherapySynthetic Immunology	2017	54

Page 1